Antimicrobial Stewardship

Penicillin continues to be an important therapy for treating syphilis. Here is a review of the literature in comparing one of the first antibiotics to non-penicillin treatments for non-neurological syphilis.

4-way trial assesses non-prescription interventions, including 2 nasal sprays, for reducing seasonal respiratory illness and related antibiotic use.

The study examines how pathogenicity-related gene clusters integrate into Salmonella's genome to affect disease ability.

Investigators found that 10 days of antibiotics is common for acute otitis media despite that 5 to 7 days is advised by US and international guidelines.

This updated guidance incorporates new treatment strategies and recommendations based on the latest data on antimicrobial resistance.

There is a high potential for ActivePure Medical’s technology to enhance patient safety and reduce healthcare costs by minimizing harmful pathogens in complex healthcare environments.

Analyzing data from over 4.6 million sinusitis cases, the study emphasizes the need for focused efforts to improve adherence to treatment guidelines and ensure antibiotics are used correctly.

The World Health Organization (WHO) warns of a moderate global risk to the presence of the pathogen, hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23, as it has been reported in at least 1 country in all 6 WHO Regions.

Omadacycline (Nuzyra) maintained its potency over time and did not show a decrease in effectiveness.

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

SHEA supports funding to address antimicrobial resistance in light of heightened challenges during the COVID-19 pandemic.

A pilot study looked at offering this form of pre-exposure prophylaxis (PrEP) to a select population to see if it could be effective in preventing sexually transmitted infections (STIs).

Paratek Pharmaceuticals has announced results from a Phase 3 study of omadacycline (Nuzyra), demonstrating its non-inferiority to moxifloxacin in treating moderate to severe community-acquired bacterial pneumonia.

Participants using nasal sprays experienced significantly shorter illness durations and reduced antibiotic usage compared to those receiving usual care.

The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.

A recent report from the CDC highlights how the COVID-19 pandemic has heightened antimicrobial resistance, resulting in a 20% increase in hospital-onset infections caused by key resistant pathogens.

Clinicians developed an algorithm and screening questionnaire for outpatient penicillin allergy evaluation, designed to stratify patients into high- and low-risk penicillin allergy groups. Here is the sample questionnaire to consider for use in clinics.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

A new study demonstrates that the continuous infusion of β-lactam antibiotics could offer better clinical outcomes in treating sepsis, despite the nuanced statistical results.

Meta-analysis revealing higher 90-day mortality with intermittent than continuous infusion of ß-lactams for sepsis prompts call for latter to be standard of care.

Jason Roberts, PhD, notes that the BLING study has been a great success for infectious diseases and critical care as a research program, providing strong evidence supporting a meaningful intervention for patients, specifically in clinical cure rates and the occurrence of infections with multiresistant organisms.

Jason Roberts, PhD, discusses insights from the BLING III trial, outlining its study design and primary outcomes. His analysis centers on the clinical benefits of continuous infusions while addressing the complexities of antibiotic administration in critical care. This is part 1 of a 2-part series.

Berkeley Heights, NJ-based biopharmaceutical company, CorMedix, is working towards an expanded indication for its DefenCath product, for the prevention of these healthcare-associated infections.

Understanding the evolving trends in antibiotic resistance among S aureus infections, commonly treated empirically with oral non–β-lactam antibiotics, is essential for guiding effective treatment strategies.

While the global clinical pipeline for antibacterial treatments displays notable activity, it remains inadequate to address the challenges of antimicrobial resistance.